BIBN 99: structure given in first source; a highly selective M2 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 132712 |
| CHEMBL ID | 4468100 |
| SCHEMBL ID | 194898 |
| MeSH ID | M0213710 |
| Synonym |
|---|
| pentanamide, n-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11h-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-n-ethyl-2,2-dimethyl- |
| n-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11h-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-n-ethyl-2,2-dimethylpentanamide |
| 145301-48-0 |
| bibn-99 |
| bibn 99 |
| L008252 |
| n-[3-[1-[2-(8-chloro-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-n-ethyl-2,2-dimethylpentanamide |
| SCHEMBL194898 |
| DTXSID00162975 |
| CHEMBL4468100 , |
| bdbm50525141 |
| AKOS040747968 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 0.0302 | 0.0000 | 0.6902 | 10.0000 | AID1598775 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.1738 | 0.0000 | 0.7951 | 9.1201 | AID1598777 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 1.4454 | 0.0000 | 0.7292 | 6.9183 | AID1598778 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 1.0715 | 0.0000 | 0.5972 | 9.1201 | AID1598774 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 0.7763 | 0.0000 | 0.5405 | 7.7600 | AID1598776 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1598768 | Selectivity ratio of Ki for human muscarinic M4 receptor expressed in stable CHO-K1 cells to Ki for human muscarinic M2 receptor expressed in stable CHO-K1 cells | |||
| AID1598778 | Displacement of [3H]-NMS from human muscarinic M5 receptor expressed in CHO-K1 cells by scintillation counting method | |||
| AID1598767 | Selectivity ratio of Ki for human muscarinic M3 receptor expressed in stable CHO-K1 cells to Ki for human muscarinic M2 receptor expressed in stable CHO-K1 cells | |||
| AID1598777 | Displacement of [3H]-NMS from human muscarinic M4 receptor expressed in CHO-K1 cells by scintillation counting method | |||
| AID1598774 | Displacement of [3H]-NMS from human muscarinic M1 receptor expressed in CHO-K1 cells by scintillation counting method | |||
| AID1598766 | Selectivity ratio of Ki for human muscarinic M1 receptor expressed in stable CHO-K1 cells to Ki for human muscarinic M2 receptor expressed in stable CHO-K1 cells | |||
| AID1598769 | Selectivity ratio of Ki for human muscarinic M5 receptor expressed in stable CHO-K1 cells to Ki for human muscarinic M2 receptor expressed in stable CHO-K1 cells | |||
| AID1598775 | Displacement of [3H]-NMS from human muscarinic M2 receptor expressed in CHO-K1 cells by scintillation counting method | |||
| AID1598776 | Displacement of [3H]-NMS from human muscarinic M3 receptor expressed in CHO-K1 cells by scintillation counting method | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.75) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||